

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 March 2025 (20.03.2025)



(10) International Publication Number
WO 2025/056679 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) *A61K 40/42* (2025.01)
A61K 35/00 (2006.01) *A61P 35/00* (2006.01)
A61K 35/17 (2025.01) *C07K 14/725* (2006.01)
C07K 14/195 (2006.01) *C07K 14/74* (2006.01)
C07K 14/435 (2006.01) *C12N 15/62* (2006.01)
C07K 14/44 (2006.01) *A61K 40/32* (2025.01)
A61K 40/11 (2025.01) *A61K 39/00* (2006.01)

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2024/075498

(22) International Filing Date:

12 September 2024 (12.09.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23197786.9 15 September 2023 (15.09.2023) EP

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(71) Applicant: **MEDIGENE IMMUNOTHERAPIES GMBH** [DE/DE]; Lochhamer Strasse 11, 82152 Planegg-Martinsried (DE).

(72) Inventors: **LONGINOTTI, Giulia**; Christrosenweg 8, 81377 München (DE). **CATARINELLA, Mario**; Niederhiedernstr. 9, 81375 München (DE). **DAVARI, Kathrin**; Ulmenstr. 14, 82362 Weilheim (DE). **SALVERMOSER, Melanie**; Richard-Wagner-Weg 4, 82178 Puchheim (DE).

(74) Agent: **WEINZIERL, Gerhard** et al.; c/o Schiweck Weinzierl Koch, Ganghoferstrasse 68b, 80339 Munich (DE).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: T-CELL RECEPTOR AGAINST mKRAS₇₋₁₆ G12V

(57) Abstract: The present invention relates to a TCR characteriyed by its CDR sequences of the α chain variable region and the β chain variable region and by its antigenic specificity to a particular mutated KRAS epitope or a fragment thereof presented in the context of a MHC class I molecule. The present invention further relates to a nucleic acid, a vector, and a host cell comprising the abovementioned. The present invention further relates to a method for obtaining said TCR and to a pharmaceutical or diagnostic composition. The invention also relates to the abovementioned for use as a medicament or for use in a method of diagnosing, detecting, preventing, and/or treating cancer. Further, the invention relates to a method of detecting the presence of a cancer in a subject *in vitro*, by applying within said method said TCR, said nucleic acid, said vector, said host cell, and/or said pharmaceutical composition, and the use of said TCR, said nucleic acid, and/or said vector for generating modified lymphocytes. Finally, the present invention relates to a kit.

WO 2025/056679 A1